Authors: Xavier Calvet, Miquel Àngel Ruíz, Angelina Dosal, Laura Moreno, Maria López, Ariadna Figuerola, David Suarez, Mireia Miquel, Albert Villoria, Emili Gené
DOI: 10.1371/journal.pone.0045604
Abstract Summary
Ferric carboxymaltose (FCM) proves more cost-effective than iron sucrose for treating iron deficiency, despite higher drug costs. FCM allows 1000mg doses versus 200mg, requiring fewer infusions. Analysis of 111 patients showed FCM saved €30-67 per patient annually, with 97% of simulations favoring FCM when including patient costs.
Why Brain? 🧠
Ferric carboxymaltose reduces iron deficiency treatment costs by 10-19% versus ferric sucrose despite higher drug costs, as fewer infusions are needed due to higher dosing capacity per session.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
